Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”). The target purchase price is $0.80 per Share, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of $0.75 per Share.
The Company expects the Arrangement to be completed in the second quarter of 2026, subject to the satisfaction or waiver of all conditions to the Arrangement. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange (“TSX”) and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws. The final consideration payable under the Arrangement is expected to be announced by press release in advance of the closing of the Arrangement.
